[Cannabis and cannabinoids-easier access, hype and disappointment : What has been confirmed in therapy?]
Cannabis und Cannabinoide – erleichterter Zugang, Hype und Enttäuschung : Was ist gesichert in der Therapie?
Cachexia
Multiple sclerosis
Nausea
Pain management
Palliative care
Journal
Der Internist
ISSN: 1432-1289
Titre abrégé: Internist (Berl)
Pays: Germany
ID NLM: 0264620
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
27
1
2019
medline:
2
10
2019
entrez:
26
1
2019
Statut:
ppublish
Résumé
Cannabis products are being increasingly liberalized all over the world and there is a huge interest in cannabis-based medicine. Presentation of current studies on the efficacy of different cannabis-based medicine for the treatment of various diseases CURRENT DATA: In German pharmaceutical legislation, nabiximols is approved for the treatment of moderate to severe therapy-resistant spasticity in multiple sclerosis and nabilone is approved for the treatment of therapy-resistant chemotherapy-associated nausea and vomiting. In case of therapy failure cannabinoids, as part of an individual therapeutic attempt, may be considered for the treatment of chronic pain (neuropathic pain, cancer pain, non-neuropathic noncancer pain), cachexia in human immunodeficiency virus as well as for Dravet and Lennox-Gastaut syndrome. From the authors' perspective there is not enough evidence for the use in chemotherapy-associated nausea and vomiting and chronic non-neuropathic pain. Currently, a wide use of cannabinoids does not seem probable in the near future. Further studies involving more patients and evaluating long-term effects are necessary.
Sections du résumé
BACKGROUND
Cannabis products are being increasingly liberalized all over the world and there is a huge interest in cannabis-based medicine.
OBJECTIVES
Presentation of current studies on the efficacy of different cannabis-based medicine for the treatment of various diseases CURRENT DATA: In German pharmaceutical legislation, nabiximols is approved for the treatment of moderate to severe therapy-resistant spasticity in multiple sclerosis and nabilone is approved for the treatment of therapy-resistant chemotherapy-associated nausea and vomiting. In case of therapy failure cannabinoids, as part of an individual therapeutic attempt, may be considered for the treatment of chronic pain (neuropathic pain, cancer pain, non-neuropathic noncancer pain), cachexia in human immunodeficiency virus as well as for Dravet and Lennox-Gastaut syndrome. From the authors' perspective there is not enough evidence for the use in chemotherapy-associated nausea and vomiting and chronic non-neuropathic pain.
CONCLUSIONS
Currently, a wide use of cannabinoids does not seem probable in the near future. Further studies involving more patients and evaluating long-term effects are necessary.
Identifiants
pubmed: 30680416
doi: 10.1007/s00108-019-0556-0
pii: 10.1007/s00108-019-0556-0
doi:
Substances chimiques
Cannabinoids
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
309-314Références
Lancet Neurol. 2010 Aug;9(8):807-19
pubmed: 20650402
Eur Neurol. 2014;72(3-4):132-41
pubmed: 25095894
Dtsch Arztebl Int. 2017 Sep 22;114(38):627-634
pubmed: 29017688
Curr Neurol Neurosci Rep. 2018 Feb 13;18(2):8
pubmed: 29442178
Pain. 2016 Feb;157 Suppl 1:S23-32
pubmed: 26785153
Cochrane Database Syst Rev. 2018 Nov 08;11:CD012954
pubmed: 30406638
Clin Pharmacol Ther. 2017 Feb;101(2):230-238
pubmed: 27859024
Neurotherapeutics. 2015 Oct;12(4):699-730
pubmed: 26264914
J Pain Symptom Manage. 2006 Jan;31(1):58-69
pubmed: 16442483
Pain. 2011 Oct;152(10):2204-5
pubmed: 21764514
Nature. 2015 Sep 24;525(7570):S10-1
pubmed: 26398731
Mol Pharmacol. 1988 Nov;34(5):605-13
pubmed: 2848184
Cochrane Database Syst Rev. 2018 Nov 08;11:CD012853
pubmed: 30407616
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Br Foreign Med Rev. 1840 Jul;10(19):225-228
pubmed: 30161735
Adv Pharmacol. 2017;80:169-206
pubmed: 28826534
Eur J Pain. 2018 Oct;22(9):1547-1564
pubmed: 30074291
Concussion. 2017 Oct 04;2(4):CNC49
pubmed: 30202590
J Med Toxicol. 2017 Mar;13(1):71-87
pubmed: 28000146
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):220-234
pubmed: 29400010
Epilepsia. 2019 Jan;60(1):6-19
pubmed: 30515765
Lancet Neurol. 2015 Feb;14(2):162-73
pubmed: 25575710
Drugs. 2018 Nov;78(17):1791-1804
pubmed: 30390221
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569
Cochrane Database Syst Rev. 2018 Mar 07;3:CD012182
pubmed: 29513392